UNSPSC 51141535: Cabergoline

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C26H37N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LL60K9J05T, chemically known as ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)- but generally known as cabergoline, which bears US NIH Compound Identifier 54746. Cabergoline most often comes in base and diphosphate forms.

UNSPSC 51141535 Cabergoline is a Commodity code that nominally designates a single pharmaceutical product, but the recent state and local activity tagged under this code does not reflect procurement of cabergoline itself. Instead, issuing bodies are using the code to solicit naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing arrangements and direct-to-manufacturer initiatives. The work being solicited is pharmaceutical procurement at scale — counties seeking emergency-response medications with quarterly delivery cycles, state health commissions gathering market intelligence on direct manufacturer contracting models to reduce intermediaries and costs, and multistate cooperative purchasing alliances establishing framework agreements for generic drugs and OTC products across participating jurisdictions. The issuing bodies include county health departments, state HHS commissions, and multistate purchasing cooperatives administering shared procurement on behalf of state and local government facilities.

Activity is concentrated in Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon. Representative recent solicitations include Seminole County, Florida's IFB 60459723LAS posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026, response date; the Texas Health and Human Services Commission's RFI HHS0017013 posted April 3, 2026, to explore direct-to-manufacturer prescription fulfillment models; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The Minnesota RFP specifies that awarded vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), comply with cGMP and DSCSA, and accept a 3 percent administrative fee on all purchases, with pricing weighted at 75 percent of evaluation. The code shows material recent activity, but the mismatch between its nominal scope (cabergoline) and actual procurement (broad pharmaceutical categories and systems) signals either category misuse in local procurement systems or an artifact of how issuing bodies tag pharmaceutical solicitations.